Information:
Fel:
ID
14274
Beskrivning
A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00252135
Länk
https://clinicaltrials.gov/show/NCT00252135
Nyckelord
Versioner (1)
- 2016-04-07 2016-04-07 -
Rättsinnehavare
CC BY-NC 3.0
Uppladdad den
7 april 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Asthma NCT00252135
Eligibility Asthma NCT00252135
- StudyEvent: Eligibility
Similar models
Eligibility Asthma NCT00252135
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
informed consent
Item
signed informed consent document (in the case of a minor, consent must be given by the child's parent or legally authorized representative)
boolean
C0021430 (UMLS CUI [1])
age
Item
≥12 years of age
boolean
C0001779 (UMLS CUI [1])
moderate to severe persistent asthma
Item
physician diagnosis of moderate to severe persistent asthma
boolean
C1960047 (UMLS CUI [1])
C1960048 (UMLS CUI [2])
C1960048 (UMLS CUI [2])
positive skin test or in vitro reactivity to an aeroallergen
Item
evidence or history of positive skin test or in vitro reactivity to an aeroallergen
boolean
C0037296 (UMLS CUI [1])
C0001697 (UMLS CUI [2])
C0001697 (UMLS CUI [2])
willingness to participate fully for the duration of the study
Item
willingness to participate fully for the duration of the study (5 years)
boolean
C1321605 (UMLS CUI [1])
xolair therapy
Item
for patients in the xolair-treated cohort, have received at least one dose of xolair therapy at the time of enrollment
boolean
C1174773 (UMLS CUI [1])
contraindication to xolair therapy
Item
contraindication to xolair therapy (e.g., patients who experienced a severe hypersensitivity reaction to xolair)
boolean
C1174773 (UMLS CUI [1,1])
C1301624 (UMLS CUI [1,2])
C1301624 (UMLS CUI [1,2])
asthma exacerbation
Item
acute asthma exacerbation within the previous 2 weeks of screening requiring any of the following: initiation of systemic corticosteroids, increased doses of systemic corticosteroids from baseline, doubling of inhaled corticosteroids, emergency room visit, or hospitalization
boolean
C0349790 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C4039704 (UMLS CUI [2])
C2065041 (UMLS CUI [3])
C0583237 (UMLS CUI [4])
C0019993 (UMLS CUI [5])
C0040223 (UMLS CUI [1,2])
C4039704 (UMLS CUI [2])
C2065041 (UMLS CUI [3])
C0583237 (UMLS CUI [4])
C0019993 (UMLS CUI [5])
comorbidity
Item
acute flare of significant systemic disease (e.g., infection, hematologic, renal, hepatic, cardiovascular diseases, or gastrointestinal diseases), or a recent hospitalization because of their disease within the previous 2 months
boolean
C0009488 (UMLS CUI [1])
C0019993 (UMLS CUI [2])
C0019993 (UMLS CUI [2])
experimental drug
Item
use of an experimental drug within 30 days prior to study screening
boolean
C1514463 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,3])
C0304229 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,3])
cystic fibrosis
Item
diagnosis of cystic fibrosis
boolean
C0010674 (UMLS CUI [1])
prior treatment with xolair
Item
for patients in the non-xolair-treated cohort, any prior treatment with xolair
boolean
C1514463 (UMLS CUI [1,1])
C1174773 (UMLS CUI [1,2])
C1174773 (UMLS CUI [1,2])